The inclusion of NMDA receptor antagonists, AMPA receptor modulators, mGlu1 and mGlu5 inhibitors, and other agents in the therapeutic arsenal for PD not only opens new possibilities for symptom relief but also offers potential for slowing or preventing neurodegenerative progression. The gene discussed is GRM5; the disease is Parkinson disease.